CTNM FY 2022 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena

CTNMContineum Therapeutics, Inc. Class A Common Stock

$504M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$329,000

Operating Income

-$23M

Net Income

-$24M

EPS (Diluted)

$-0.97

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$51M

Total Liabilities

$11M

Stockholders' Equity

$39M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$329,000	$0	—
Operating Income	-$23M	-$29M	+20.7%
Net Income	-$24M	-$29M	+16.4%